



# Paris Portal Vein thrombosis meeting



Organizing committee  
Laure Elkrief, Virginia Hernandez-Gea,  
Marco Senzolo and Pierre-Emmanuel Rautou

**Hôtel de de Ville de Paris**  
**Place de l'Hôtel de Ville - Paris**  
**November 29<sup>th</sup> and 30<sup>th</sup> 2022**

# Paris Portal Vein thrombosis meeting

Day 1, November 29<sup>th</sup> 2022

**8h30-8h50: Welcome of participants**

**8h50-9h: Opening and introductory words (L Elkrief and P-E Rautou)**

## **9h – 12h30 Session 1: Non cirrhotic PVT**

**9h-10h30 Chair: A. Plessier (France) and F. Nery (Portugal)**

Causes and underlying mechanisms

J Poisson, France

Impact of etiological therapy

C Bureau, France

Pathophysiology of portal hypertension in PVT without cirrhosis: similarities and differences with cirrhosis

JC Garcia Pagan, Spain

*10h30 -11h Break*

**11h-12h30 Chair: D. Thabut (France) and B. Procopet (Romania)**

Non-invasive tests versus liver biopsy?

L Elkrief, France

PSVD and PVT: two separate entities?

V Paradis, France

Anticoagulation in patients with recent and chronic PVT

A Plessier, France

*12h30 - 14h Lunch break*

## **14h-15h30 Session 2: PVT in patients with cirrhosis**

**Chair: V. Hernandez-Gea (Spain) and F. Durand (France)**

Epidemiology and risk factors

F Nery, Portugal

Impact of treating the cause of cirrhosis

M Mandorfer, Austria

Anticoagulation in patients with cirrhosis to prevent and treat PVT and to prevent decompensation

A Albillos, Spain

When and how to treat PVT in a patient with simultaneous HCC (excluding PV invasion)?

M Senzolo, Italy

Management of PVT before and after liver transplantation

F Durand, France

C Toso, Switzerland

*15h30-16h Break*

## **16h-18h Session 3: Specificity of the portal venous system**

**Chair : S. Raevens (Belgium) and PE Rautou (France)**

Specificity of the portal vein wall in cirrhosis (15 min + 15 min discussion)

V Hernandez-Gea, Spain

Specificity of the portal blood in cirrhosis (15 min + 15 min discussion)

Ton Lisman, The Netherlands

**State of the art lecture: Immuno-thrombosis**

Konstantin Stark, Germany

# Paris Portal Vein thrombosis meeting

Day 2, November 30<sup>th</sup> 2022

## 8h-9h30 Session 4: Management of PVT without and with cirrhosis

Chair: A Zanetto (Italy) and L Elkrief (France)

PVT and cirrhosis: what place for anticoagulation and for interventional radiology?

D Tripathi, UK  
Lara Roberts, UK

PVT without cirrhosis: what place for anticoagulation and for interventional radiology?

A de Gottardi, Switzerland  
R Salem, USA

Prevention and management of variceal bleeding in PVT without cirrhosis: should that really be the same as in cirrhosis?

D Patch, UK

### *9h30-10h Break*

## 10h - 12h Session 5: Specific issues in PVT without cirrhosis

10h-11h Chair: L Moga (France) and L. Tellez (Spain)

Impact on quality of life

A Baiges, Spain

Fertility, contraception and pregnancy

A Payancé, France

PVT in children: specificities as compared with adults

V McLin, Switzerland

Role of patient's associations in student's training

S Hullin, AMVF, France

### Common discussion

11h – 12h Chair: S. Darwish Murad (The Netherlands) and M. Senzolo (Italy)

Portal cholangiopathy

A Shukla, India

Chronic abdominal pain, chronic enteropathy, mesenteric ischemia and intestinal necrosis

A Nuzzo, France

Symptomatic hypersplenism

S Sarin, India

Management of PVT in patients with pancreatic cancer and pancreatitis

M Primignani, Italy

### Common discussion

### *12h - 13h30 Lunch break and cultural visit of Paris*

## 13h30-18h Session 6: Consensus discussion : endpoints for studies in PVT

Chair : V. Hernandez-Gea (Spain) and P-E Rautou (France)

Classification of portal vein thrombus extension

M Ronot, France

Classification of portal vein thrombosis evolution

P Northup, USA

### *15h30-16h Break*

Timing of assessment

A Berzigotti, Switzerland

Goal of the treatment in patients with portal vein thrombosis

S Darwish Murad, the Netherlands

## 17h30-18h Concluding remarks

## Paris Portal Vein thrombosis meeting

### Scientific partners



Hepatological Diseases  
(ERN RARE-LIVER)

### Industrial partners



abbvie

COOK®



### This meeting is endorsed by

